Eli Lilly shares are rising after the company reported Q1 2026 results that beat expectations and lifted full-year guidance. Revenue jumped 56% to $19.8 billion and Lilly raised 2026 revenue outlook to $82–$85 billion as Mounjaro and Zepbound demand stayed strong.
1. What’s driving the move
Eli Lilly (LLY) is climbing today as investors react to a strong Q1 2026 earnings report and a higher full-year outlook released April 30, 2026. The company posted reported EPS of $8.26 and highlighted that demand for its incretin portfolio continues to power outsized growth, prompting management to raise 2026 financial guidance. (lilly.gcs-web.com)
2. The key numbers investors are focusing on
Lilly reported Q1 2026 revenue of $19.8 billion, up 56% year over year, driven primarily by volume growth. Alongside the results, the company raised its 2026 revenue guidance to a range of $82 billion to $85 billion (a $2 billion increase versus the prior range), reinforcing expectations for another year of rapid expansion. (lilly.gcs-web.com)
3. Why the market likes the setup from here
The quarter reinforced the durability of Lilly’s cardiometabolic franchise, with GLP-1 medicines continuing to scale and helping offset pressures such as lower realized pricing. With guidance moving higher immediately following a big quarter, today’s rally reflects improved confidence that earnings power can remain elevated through 2026 as supply and access expand and demand remains strong. (americanpharmaceuticalreview.com)
4. What to watch next
Investors will be tracking whether Lilly can sustain growth while managing pricing and access dynamics, especially as competition in obesity and diabetes intensifies. Any updates on capacity, payer coverage expansion, and new indications or pipeline readouts could be the next major catalysts now that management has reset the bar higher for 2026. (fool.com)
LLY•
